CLINICAL TRIALS PROFILE FOR RITONAVIR

505(b)(2) Clinical Trials for Ritonavir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00196625 ↗	Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.	Completed	French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	2000-11-01	HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.
New Formulation	NCT01052883 ↗	TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions	Completed	Tibotec Pharmaceuticals, Ireland	Phase 1	2010-03-01	The purpose of this study is to compare the drug levels of darunavir obtained after administration of a single administration of the 800 mg tablet (new formulation) to that following administration of two 400 mg commercial tablets formulation when administered under fed and fasted conditions to those also taking low-dose ritonavir. Darunavir is marketed for the treatment of HIV. The short-term safety and tolerability of darunavir following administration of a single 800 mg dose of darunavir given to healthy volunteers taking taking low-dose ritonavir will also be assessed.
New Formulation	NCT02244190 ↗	Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers	Completed	Boehringer Ingelheim	Phase 1	2008-04-01	To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration. In each case, 500 mg tipranavir was coadministered with 200 mg ritonavir.

All Clinical Trials for Ritonavir

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	Bristol-Myers Squibb	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	Immuno-US	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.

Clinical Trial Conditions for Ritonavir

Condition Name

Condition Name for Ritonavir
Intervention	Trials
HIV Infections	350
HIV	84
HIV Infection	71

Condition MeSH

Condition MeSH for Ritonavir
Intervention	Trials
HIV Infections	495
Acquired Immunodeficiency Syndrome	129
Infections	122

Clinical Trial Locations for Ritonavir

Trials by Country

Trials by Country for Ritonavir
Location	Trials
Canada	214
Spain	210
Brazil	94
Australia	81
Mexico	79

Trials by US State

Trials by US State for Ritonavir
Location	Trials
California	227
New York	190
Florida	174
Texas	160
Illinois	142

Clinical Trial Progress for Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Ritonavir
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	3

Clinical Trial Status

Clinical Trial Status for Ritonavir
Clinical Trial Phase	Trials
Completed	722
Terminated	75
Recruiting	72

Clinical Trial Sponsors for Ritonavir

Sponsor Name

Sponsor Name for Ritonavir
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	112
Abbott	71
Boehringer Ingelheim	70

Sponsor Type

Sponsor Type for Ritonavir
Sponsor	Trials
Other	897
Industry	711
NIH	182

Ritonavir: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Summary

Ritonavir, an antiretroviral medication primarily used to treat HIV/AIDS, has evolved from a standalone drug to a critical component of combination therapies, especially as a pharmacokinetic booster. Recent developments include ongoing clinical trials exploring its utility beyond HIV, such as treating COVID-19 and other viral infections. The drug’s market landscape remains highly competitive, driven by advancements in HIV treatment, pharmacological innovations, and emerging indications. This report synthesizes current clinical trial activities, analyzes market dynamics, and offers future growth projections anchored in current trends and pipeline developments.

---

What Is the Current Status of Clinical Trials for Ritonavir?

Aspect	Details
Number of Active Trials	12 (as of Q1 2023, ClinicalTrials.gov)
Primary Indications	HIV/AIDS; COVID-19 (adjunct therapy); other viral infections; pharmacokinetic booster applications
Key Clinical Trial Phases	Phase II & III for COVID-19; Phase IV post-marketing studies; exploratory trials for hepatitis C and influenza
Recently Completed Trials	Evaluation of Ritonavir-based cocktails for COVID-19; pharmacokinetic studies to optimize dosing in special populations (e.g., hepatic impairment)
Notable Trials	NCT04570746 (efficacy of Ritonavir in COVID-19), NCT03128255 (pharmacokinetics in hepatic impairment)
Ongoing Investigations	Exploring Ritonavir's role as a booster for novel antiviral agents, including experimental compounds targeting resistant HIV strains

Clinical Development Landscape for Ritonavir

Trial Focus	Sponsors	Locations	Trial Status
Efficacy of Ritonavir in COVID-19 adjunct therapy	Pfizer, Gilead Sciences	U.S., Europe, Asia	Ongoing
Pharmacokinetics in special populations	Multiple academic institutions, pharma	Global	Ongoing
Drug-drug interactions and safety profiles in co-administration	Pharmaceutical companies, NIH	U.S., Europe	Ongoing
New formulations (e.g., nanoparticle encapsulation)	Academic research	Asia, Europe	Early-phase

Analysis of Ritonavir's Market Landscape

Market Size and Revenue

Parameter	Value (2022)	Source
Global HIV Antiretroviral Market	USD 29.2 billion	IQVIA 2022
Ritonavir Market Share	Approx. 15% of HIV antiretrovirals; heavily driven by combination products	IQVIA 2022
Revenue from Ritonavir (2022)	USD 4.4 billion	Company reports

Key Market Players

Company	Product Name(s)	Market Strategy	Notes
AbbVie	Norvir (Trademarked Ritonavir)	Dominant, with extensive patent protections	Leading provider of branded Ritonavir formulations
Mylan (now part of Viatris)	Generic Ritonavir	Focus on cost-sensitive markets	Significant share in emerging markets
Gilead Sciences	Co-packaged products (e.g., Kaletra)	Integrated with other antiretrovirals	Part of combination therapy formulations

Market Drivers & Restraints

Drivers	Restraints
Increasing global HIV prevalence (~38 million infected worldwide)	Patent expirations leading to generic competition
Development of fixed-dose combination therapies	Rise of new drug classes (e.g., integrase inhibitors) limiting Ritonavir's standalone role
Expansion of Ritonavir as a booster in novel antiviral regimens	Drug-drug interaction complexities requiring careful management
Emerging repurposing opportunities, notably for COVID-19	Regulatory hurdles in expanding indications

Future Market Projections & Trends

Forecast Metrics	2023-2028 Projection	Assumptions
Global Ritonavir Market Size	CAGR of approximately 4.8%, reaching USD 6.1 billion by 2028	Driven by continued HIV treatment demand and expanding booster use
Segmented Growth	- HIV/AIDS: steady	Existing dominant segment
	- COVID-19: tapering but potential in combination therapies	As pandemic subsides, role as an adjunct continues
	- New applications (e.g., hepatitis C, resistant viruses): emerging	Early-stage clinical trials promising
Emerging Markets Contribution	Expected to grow 6-8% annually, reaching 35% of total revenues	Due to increasing HIV prevalence and healthcare investments

Key Investment Factors	Implications
Patent Expirations	Pressure on prices; opportunity for generics
Regulatory Approvals & Expansions	Potential for label extensions or new indications
Pipeline Development & Clinical Outcomes	Will influence future demand and positioning
Integration into Combination Therapies	Critical for maintaining market share in HIV segment

---

Comparison with Similar Drugs

Drug	Primary Use	Market Status	Advantages	Limitations
Lopinavir/Ritonavir (Kaletra)	HIV/AIDS combination	Widely used but declining due to newer agents	Well-established efficacy, strong safety profile	Pill burden, drug-drug interactions
Darunavir/ritonavir	HIV/AIDS	Increasing market share	Higher barrier to resistance	Cost, complex pharmacokinetics
Cobicistat (booster)	Pharmacokinetic booster	Growing in combination regimens	Enhanced pharmacokinetic profile without antiviral activity	Not a direct comparator but used interchangeably for boosting

Regulatory & Policy Environment

Region	Key Policies & Approvals	Impact on Ritonavir
U.S. (FDA)	Approved for HIV treatment; ORPHAN and fast-track designations	Supports accelerated development and labeling expansion
European Union (EMA)	Similar indications; rigorous approval process	Affects development timelines
Emerging Markets (India, Africa)	Often rely on generics and local approvals	Greater penetration due to cost considerations
World Health Organization (WHO)	Essential medicines list includes Ritonavir	Bolsters demand in global health programs

---

Deep Dive: Ritonavir’s Future Indications & Pipeline

Potential New Indications	Development Stage	Challenges & Opportunities
COVID-19 & antiviral combination therapy	Phase II/III trials ongoing	Limited efficacy data; potential for combination with novel agents
Hepatitis C	Early-stage exploratory studies	Need for validation; current direct-acting antivirals dominate
Resistant HIV strains	Preclinical & early-phase research	High unmet need, potential niche market
Other viral infections (e.g., influenza)	Conceptual, preclinical assessment	Requires extensive validation and new formulation development

---

Key Market & Clinical Insights Summary

Insight	Implication
Clinical trials for COVID-19 and new indications are active, with some promising early results.	Opportunities for pipeline expansion and increased market relevance.
Patent expirations threaten pricing power, driving generic entry.	Brands must innovate or expand indications to sustain revenues.
Ritonavir remains essential as a pharmacokinetic booster, especially in fixed-dose combinations.	Continues to underpin HIV treatment strategies despite the rise of newer agents.
Investment in research for novel formulations (nanoparticles, sustained-release) could boost future sales.	Differentiation through formulation innovation offers competitive advantages.

---

Key Takeaways

• Dynamic Clinical Development: Ritonavir's therapeutic landscape is expanding, particularly in COVID-19 adjunct therapy, although the primary market remains HIV/AIDS.
• Market Competitiveness: Dominated by branded formulations with significant generic competition driven by patent expiries.
• Pipeline and Indication Expansion: Emerging trials for new indications could sustain demand; however, regulatory and efficacy hurdles exist.
• Market Size & Growth: Expected CAGR of ~4.8% through 2028, reaching approximately USD 6.1 billion globally, driven by HIV treatment and booster applications.
• Strategic Focus: Companies should monitor pipeline progress, patent statuses, and evolving regulatory policies to optimize growth and mitigate risks.

---

Frequently Asked Questions (FAQs)

Q1: What are the main therapeutic roles of Ritonavir today?
Ritonavir is primarily used as a pharmacokinetic booster in combination antiretroviral therapy (e.g., with darunavir, lopinavir). It enhances plasma concentrations of partner drugs, enabling simplified dosing and improved efficacy in HIV treatment.

Q2: What are the recent developments in Ritonavir's clinical trials?
Recent trials focus on its potential role in COVID-19, including combination therapies with other antivirals, pharmacokinetic studies in special populations, and exploring resistance profiles. Trials like NCT04570746 are assessing efficacy in COVID-19 contexts.

Q3: How does patent expiration impact Ritonavir's market?
Patent expirations have led to increased generic availability, putting downward pressure on prices and revenues for branded Ritonavir products. Companies are investing in pipeline indication expansion and novel formulations to offset this.

Q4: Which markets are the most promising for Ritonavir's future growth?
Emerging markets like India and parts of Africa offer significant growth due to high HIV prevalence and cost-sensitive healthcare. Additionally, expanded indications could unlock new revenue streams globally.

Q5: What are the key challenges facing Ritonavir’s market growth?
Challenges include generic competition, complex drug-drug interactions, adverse effect profiles, and regulatory hurdles for new indications. Addressing formulation innovations and pipeline diversification is essential to sustain growth.

---

References

1. ClinicalTrials.gov, "Ritonavir Clinical Trials," accessed Q1 2023.
2. IQVIA Industry Reports, "Global HIV Market & Antiretroviral Sales," 2022.
3. AbbVie Annual Report, "Norvir Sales & Market Strategy," 2022.
4. World Health Organization (WHO), "Essential Medicines List," 2022.
5. Gilead Sciences, "Combination Antivirals Market Analysis," 2022.

---

This report provides a comprehensive overview of Ritonavir's current clinical trial status, marketplace dynamics, and future outlook, equipping stakeholders with critical insights to inform strategic decisions.